Personalized treatment in non-small cell lung cancer: From diagnostics to therapy;Személyre szabott kezelés nem-kissejtes tüdőrákban - A diagnosztikától a terápiáig

Orvosi Hetilap

Volumn 153, Issue 23, 2012, Pages 909-916

  Moldvay, Judit ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

EGFR TKI; lung cancer; molecular targeted treatment; mutation analy; personalized treatment

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; COMORBIDITY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE;

EID: 84862012984     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2012.29397     Document Type: Article

References (26)

1. Strausz, J., Csoma, Zs., Kovács, G., et al.: Korányi Bulletin. [Korányi Bulletin] 2011, 1, 16. [Hungarian]
2. Zheng, Z., Chen, T., Li, X., et al.: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med., 2007, 356, 800-808. (Pubitemid 46294612)
3. Martin, L. P., Hamilton, T. C., Schilder, R. J.: Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res., 2008, 14, 1291-1295. (Pubitemid 351413906)
4. Okuda, K., Sasaki, H., Dumontet, C., et al.: Expression of excision repair cross-complementation group 1 and class III betatubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer, 2008, 62, 105-112.
5. Sun, J. M., Han, J., Ahn, J. S., et al.: Signifi cance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J. Thorac. Oncol., 2011, 6, 1392-1399.
6. Bepler, G., Sommers, K. E., Cantor, A., et al.: Clinical effi cacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 1112-1118.
7. Avien-Ronen, S., Blackhall, F. H., Shepherd, F. A., et al.: K-ras mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer, 2006, 8, 30-38. (Pubitemid 44336241)
8. Yoshimasu, T., Oura, S., Ohta, F., et al.: Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J. Thorac. Oncol., 2011, 6, 1658-1662.
9. Camidge, D. R., Kono, S. A., Lu, X., et al.: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol., 2011, 6, 774-780.
10. Simon, G. R., Schell, M. J., Begum, M., et al.: Preliminary indication of survival benefi t from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer, 2011, 112, 2021-2029.
11. Vilmar, A., Garcia-Foncillas, J., Huarriz, M., et al.: RT-PCR versus immunohistochemistry for correlation and quantifi cation of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer, 2012, 75, 306-312. [Available online 13 October 2011]
12. Sandler, A., Gray, R., Perry, M. C., et al.: Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell ling cancer. N. Engl. J. Med., 2006, 355, 2542-2550. (Pubitemid 44917502)
13. Pirker, R., Pereira, J. R., Szczesna, A., et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373, 1525-1531.
14. O'Byrne, K. J., Gatzemeier, U., Bondarenko, I., et al.: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol., 2011, 12, 795-805.
15. Schwab, R., Pinter, F., Moldvay, J., et al.: Modern treatment of lung cancer: case 1. Amplifi cation and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefi tinib. J. Clin. Oncol., 2005, 23, 7736-7738. (Pubitemid 46291837)
16. Lynch, T. J., Bell, D. W., Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefi tinib. N. Engl. J. Med., 2004, 350, 2129-2139. (Pubitemid 38637993)
17. Paez, J. G., Janne, P. A., Lee, J. C., et al.: EGFR mutations in lung cancer: correlation with clinical response to gefi tinib therapy. Science, 2004, 304, 1497-1500. (Pubitemid 38720929)
18. Riely, G. J., Marks, J., Pao, W.: KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc., 2009, 6, 201-205.
19. Shigematsu, H., Lin, L., Takahashi, T., et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, 97, 339-346. (Pubitemid 40425952)
20. Pinter, F., Papay, J., Almasi, A., et al.: Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J. Mol. Diagn., 2008, 10, 160-168. (Pubitemid 351428398)
21. Cappuzzo, F., Jänne, P. A., Skokan, M., et al.: MET increased gene copy number and primary resistance to gefi tinib therapy in non-small-cell lung cancer patients. Ann. Oncol., 2009, 20, 298-304.
22. Becker, A., Crombag, L., Heideman, D. A. M., et al.: Retreatment with erlotinib. Regain of EGFR-TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer, 2011, 47, 2603-2606.
23. Watanabe, S., Tanaka, J., Ota, T.: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefi ted from prior effective gefi tinib therapy: a retrospective analysis. BMC Cancer, 2011, 11, 1.
24. Just, P. A., Cazes, A., Audebourg, A., et al.: Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. Lung Cancer, 2011 Dec 6. [Epub ahead of print]
25. Shaw, A. T., Yeap, B. Y., Solomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol., 2011, 12, 1004-1012.
26. www.ClinicalTrials.gov